Humacyte, Inc.
HUMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $1 |
| % Growth | – | -100% | 23.9% | – |
| Cost of Goods Sold | $7 | $77 | $8 | $61 |
| Gross Profit | -$7 | -$77 | -$7 | -$60 |
| % Margin | – | – | -427.5% | -4,756.8% |
| R&D Expenses | $89 | $77 | $63 | $61 |
| G&A Expenses | $26 | $23 | $23 | $21 |
| SG&A Expenses | $26 | $20 | $23 | $21 |
| Sales & Mktg Exp. | $0 | -$3 | $0 | $0 |
| Other Operating Expenses | -$7 | -$73 | -$8 | -$61 |
| Operating Expenses | $107 | $23 | $78 | $21 |
| Operating Income | -$114 | -$100 | -$85 | -$81 |
| % Margin | – | – | -5,404.3% | -6,429.8% |
| Other Income/Exp. Net | -$34 | -$11 | $73 | $55 |
| Pre-Tax Income | -$149 | -$111 | -$12 | -$26 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$149 | -$111 | -$12 | -$26 |
| % Margin | – | – | -764.5% | -2,096.4% |
| EPS | -1.26 | -1.07 | -0.12 | -0.66 |
| % Growth | -17.8% | -791.7% | 81.8% | – |
| EPS Diluted | -1.26 | -1.07 | -0.12 | -0.66 |
| Weighted Avg Shares Out | 118 | 103 | 103 | 40 |
| Weighted Avg Shares Out Dil | 118 | 103 | 103 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $5 | $3 | $0 |
| Interest Expense | $9 | $7 | $6 | $4 |
| Depreciation & Amortization | $7 | $8 | $8 | $8 |
| EBITDA | -$132 | -$96 | -$76 | -$73 |
| % Margin | – | – | -4,879.7% | -5,777.3% |